According to a research report published earlier today by Brean Murray Carret, Masimo Corporation MASI is scheduled to report Q4:11 results this evening after close.
In the report, Brean Murray Carret commented, “As we had highlighted in our 1/13 update, a careful dig through our model suggests Q4 estimates could be modestly exceeded and 2012 estimates are appropriate; there also appears to be a number of underappreciated tailwinds (new products, OEM partners w/ Rainbow, manufacturing cost reduction efforts) that could further improve the overall picture as 2012 progresses despite the presence of a number of headwinds on which the Street has attached much focus. Our target price of $24 reflects a 19x multiple applied to our 2012 estimate.”
Brean Murray Carret maintains its Buy rating on Masimo, which closed yesterday at $21.12.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Posted In: Analyst ColorReiterationAnalyst RatingsBrean Murray Carret & CompanyHealth CareHealth Care Equipment
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in